Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 297,211 shares of the firm's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the sale, the director directly owned 2,962 shares in the company, valued at $68,896.12. The trade was a 99.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Stock Performance
Shares of NASDAQ DYN opened at $23.83 on Thursday. The company has a market capitalization of $3.94 billion, a PE ratio of -7.40 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The company's fifty day moving average price is $19.00 and its 200 day moving average price is $18.28. Dyne Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $25.00.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the business earned ($1.05) EPS. On average, research analysts predict that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current year.
Hedge Funds Weigh In On Dyne Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics in the first quarter worth approximately $26,000. Strs Ohio acquired a new position in Dyne Therapeutics in the 4th quarter valued at $51,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics in the 4th quarter valued at $84,000. Steward Partners Investment Advisory LLC lifted its holdings in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock valued at $95,000 after purchasing an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company's stock valued at $136,000 after purchasing an additional 1,440 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 15th. Sanford C. Bernstein boosted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a "buy" rating for the company. Finally, Wall Street Zen raised shares of Dyne Therapeutics from a "strong sell" rating to a "sell" rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $34.17.
Check Out Our Latest Research Report on DYN
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
